Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06632509 · ClinicalTrials.gov registry record
BD SiteRite(TM) 9 Ultrasound System - Clinical Study
A clinical trial, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 149
- Enrollment target
NCT06632509: Completed study, sponsored by Becton, Dickinson and Company.
NCT06632509 is a clinical trial that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 149 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06632509 has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 149 participants
- Enrollment target
Study Summary
This post-market study is being conducted to generate safety and performance data on the SiteRite 9 System. The data will be utilized to support regional registrations (for example, EU MDR), and document any unforeseen residual risks.
Primary Outcome
The BD SiteRiteTM 9 Ultrasound System is able to visualize the target vasculature (\>=70% with a 95% confidence interval)
Interventions
- DEVICE BD SiteRite(TM) 9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2026-01-09 |
What the finished NCT06632509 record still lists
NCT06632509 is an observational study that tracks outcomes without assigning an intervention. The registered 149 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which BD SiteRite(TM) 9 is the first listed.
NCT06632509 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06632509 about?
NCT06632509 is a clinical study titled "BD SiteRite(TM) 9 Ultrasound System - Clinical Study". This post-market study is being conducted to generate safety and performance data on the SiteRite 9 System. The data will be utilized to support regional registrations (for example, EU MDR), and document any unforeseen residual risks.
What is the current status of trial NCT06632509?
This trial is currently completed. The enrollment target is 149 participants. The study started on 2025-11-12. Estimated completion is 2026-01-09.
What interventions are being tested in trial NCT06632509?
The interventions under investigation include: BD SiteRite(TM) 9 (DEVICE).
Who is sponsoring clinical trial NCT06632509?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04188535 · 149 participants · NA
Serial MRI Scans During Radiation Therapy
- NCT05828511 · 149 participants · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI